Top Page
4DMedical Ltd
(Sydney:4DX)
4DMedical Ltd (4DX) vs. iShares MSCI Australia ETF (EWA)
4DMedical Ltd Business Overview & Revenue Model
4DMedical Ltd Financial Statement Overview
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.86M | 3.75M | 282.18K | 1.05M | 216.98K | 1.23M |
| Gross Profit | 5.48M | 3.52M | 248.03K | 280.62K | 125.13K | -8.13M |
| EBITDA | -44.64M | -31.86M | -33.74M | -36.34M | -18.04M | -15.77M |
| Net Income | -39.54M | -35.98M | -31.46M | -24.59M | -21.42M | -21.98M |
Balance Sheet | ||||||
| Total Assets | 102.01M | 120.02M | 92.92M | 74.31M | 92.64M | 15.82M |
| Cash, Cash Equivalents and Short-Term Investments | 15.95M | 30.61M | 69.58M | 51.11M | 80.88M | 8.43M |
| Total Debt | 4.82M | 5.12M | 5.14M | 6.24M | 1.69M | 16.49M |
| Total Liabilities | 42.15M | 49.09M | 21.46M | 14.80M | 9.28M | 27.63M |
| Stockholders Equity | 59.86M | 70.93M | 71.46M | 59.51M | 83.36M | -11.81M |
Cash Flow | ||||||
| Free Cash Flow | -30.37M | -31.17M | -23.38M | -28.35M | -15.25M | -8.81M |
| Operating Cash Flow | -30.28M | -30.87M | -22.65M | -25.27M | -14.52M | -7.65M |
| Investing Cash Flow | -1.52M | -40.04M | -1.61M | -3.50M | -580.45K | -786.45K |
| Financing Cash Flow | -127.96K | 31.94M | 42.73M | -995.47K | 87.55M | 13.78M |
4DMedical Ltd Technical Analysis
4DMedical Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | AU$1.20B | 71.61 | 9.23% | ― | 10.79% | 5.20% | |
70 Outperform | $19.92B | 53.82 | 20.61% | 2.19% | 6.35% | 5.97% | |
69 Neutral | $115.36B | 27.69 | 15.38% | 1.73% | 8.00% | 9.09% | |
64 Neutral | AU$18.84M | 140.00 | -3.11% | ― | 89.13% | 69.57% | |
54 Neutral | AU$203.28M | ― | -37.20% | ― | ― | 32.02% | |
51 Neutral | $7.50B | 0.32 | -61.87% | 2.27% | 17.10% | 1.59% | |
39 Underperform | AU$114.05M | ― | -52.37% | ― | 471.29% | -4.58% |
4DMedical Ltd Corporate Events
4DMedical Limited has issued 20,294 fully paid ordinary shares following the exercise of options under its Long Term Incentive Plan. This issuance was conducted without a disclosure to investors, in compliance with the Corporations Act, and a cleansing notice has been lodged with the ASX. The move aligns with regulatory requirements and reflects the company’s ongoing commitment to its incentive plans, potentially impacting its financial structure and stakeholder interests.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Ltd has announced the quotation of 20,294 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code 4DX. This move is part of an employee incentive scheme and reflects the company’s ongoing efforts to strengthen its market position and incentivize its workforce, potentially impacting its operational dynamics and stakeholder interests positively.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
Olympus Corporation has launched a new campaign for SeleCT™ Screening in the United States, utilizing 4DMedical’s lung density analysis technology to identify candidates for the Olympus Spiration™ Valve System. This large-scale deployment of AI-based lung imaging marks a significant commercial expansion for 4DMedical, enhancing its clinical utility in early detection and therapy enablement. The partnership addresses the underdiagnosis of COPD, particularly emphysema, and expands 4DMedical’s presence in interventional respiratory care, offering substantial commercial growth opportunities.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Ltd has announced the quotation of 5,000 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code 4DX. This move is part of an employee incentive scheme, indicating the company’s commitment to rewarding its workforce and potentially enhancing employee engagement and retention.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Limited has issued nearly 15 million shares as part of the earnout consideration for its acquisition of Imbio Inc. This strategic move is expected to strengthen 4DMedical’s position in the healthcare industry, particularly in the field of lung health, by integrating Imbio’s capabilities and expanding its technological offerings.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Ltd has announced the quotation of 14,964,623 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code 4DX, effective May 29, 2025. This move is part of a previously announced transaction and is expected to bolster the company’s market presence and provide additional capital for its ongoing operations and strategic initiatives.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Limited has released an investor presentation providing a general overview of the company’s current activities and operations as of May 27, 2025. The presentation is informational and not intended as a financial product advice or an offer for securities, emphasizing the company’s commitment to transparency while highlighting legal restrictions on distribution, particularly in the United States.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Limited has filed an FDA 510(k) submission for its CT:VQ™ software, a groundbreaking non-contrast CT-based lung imaging product that assesses both ventilation and perfusion in the lungs. This innovation addresses clinical and logistical challenges associated with traditional nuclear VQ imaging, offering higher resolution and accessibility by leveraging existing CT infrastructure. The company anticipates capturing the entire market of one million annual nuclear VQ scans in the U.S., with potential global market expansion. CT:VQ™ is expected to drive long-term growth in demand for lung assessments, transforming pulmonary care by making comprehensive evaluations more accessible, even in facilities without nuclear medicine capabilities.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
4DMedical Limited has secured a commercial contract with Intermountain Health, a prominent U.S. health system, for its FDA-cleared Pulmonary Hypertension Analysis (PHA™) product. This contract, facilitated through a strategic partnership with Nuance Communications, marks the first major deployment of the PHA™ algorithm in a large health network, enhancing clinical decision-making and potentially expanding 4DMedical’s market presence. The agreement represents a significant opportunity for revenue growth as it transitions to full commercial terms, with plans to increase usage and expand to other products within the health system.
4DMedical Ltd has released its First 20 Investors Report, detailing the top investors holding significant shares in the company. The report reveals that the top 20 investors collectively hold 51.61% of the company’s issued capital, with CITICORP NOMINEES PTY LIMITED leading at 21.15%. This concentration of ownership among a few key investors could impact the company’s strategic decisions and market influence.
4DMedical Ltd has announced the application for quotation of new securities on the ASX, specifically options expiring on February 28, 2026. This move involves issuing listed options to participants of their recent SPP and placement, potentially enhancing the company’s capital structure and market presence.
4DMedical Limited announced that all resolutions proposed at its Extraordinary General Meeting were successfully passed. This outcome supports the company’s strategic initiatives, including the ratification of share issues and the approval of new options, which are expected to strengthen its financial position and operational capabilities. These developments are likely to enhance 4DMedical’s industry positioning and provide further value to its stakeholders.
4DMedical Limited reported a significant increase in operating revenue for the year-to-date FY2025, achieving a 103% rise compared to the previous period, with gross margins of 91.4%. The company is expanding its sales pipeline and has secured key contracts, including a renewal with the Cleveland Clinic and conversions of pilot programs into commercial contracts. A cost reduction program has been implemented, resulting in $6.5 million in annualized savings. The company is preparing for the FDA submission of its CT:VQ™ product, which has attracted interest from major medical centers and industry collaborators. Additionally, 4DMedical has received regulatory clearance for its CT LVAS™ in Canada and has been highlighted by Philips as a solution for improving veteran health outcomes.
4DMedical Ltd has announced the quotation of 131,498 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code 4DX. These securities were issued as part of an employee incentive scheme and are not subject to transfer restrictions, indicating a strategic move to incentivize and retain talent within the company.
4DMedical Limited has lodged a supplementary prospectus with the Australian Securities and Investments Commission, amending the terms of its New Options and Piggyback Options offers. The company has streamlined the application process for eligible participants, who will automatically be deemed to have applied for their allocation unless they choose to opt out. This move aims to simplify participation and potentially increase stakeholder engagement in anticipation of future FDA clearance for its CT:VQ technology.
4DMedical Limited has announced a change in the address of its registry office in Sydney, effective from April 14, 2025. This move is part of the company’s ongoing efforts to streamline its operations and maintain compliance with ASX regulations. The change is not expected to impact the company’s operations or its stakeholders significantly, as contact details remain unchanged.
4DMedical Limited has successfully transitioned its pilot program with Integral Diagnostics into a commercial contract, marking a significant expansion of its lung imaging technology across Victoria, Australia. This development will enhance access to 4DMedical’s advanced diagnostic tools for general practitioners, respiratory specialists, and cardiologists, improving patient outcomes through more accurate and timely diagnoses of respiratory conditions. The contract signifies strong demand for 4DMedical’s innovative solutions and reinforces its commitment to revolutionizing lung health, further solidifying its commercial presence in the Australian market.
4DMedical Limited has secured two new contracts to supply its advanced lung imaging technology for clinical trials, one with SMS Biotech for a COPD stem cell therapy trial and another with an unnamed medical device developer. This highlights 4DMedical’s growing role in the respiratory health sector and its strategic partnerships aimed at advancing lung disease treatments. Additionally, 4DMedical’s technology was featured in a US Congressional testimony by Philips, emphasizing its potential to improve veteran healthcare outcomes through enhanced pulmonary diagnostics.